Role of nitric oxide donor in methotrexate-induced testicular injury via modulation of pro-inflammatory mediators, eNOS and P-glycoprotein

• Published in: Human & experimental toxicology 2020-12, Vol.39 (12), p.1700-1709
• Main Authors: Abdelzaher, WY, Khalaf, HM, El-Hussieny, M, Bayoumi, AMA, Shehata, S, Refaie, MMM
• Format: Article
• Language: English
• Subjects: Animals; Antimetabolites, Antineoplastic - toxicity; Antioxidants; ATP Binding Cassette Transporter, Subfamily B, Member 1 - metabolism; Evaluation; Glutathione - metabolism; Glycoproteins; IL-1β; Inflammation; Inflammation Mediators - metabolism; Injection; Injuries; Interleukins; Male; Malondialdehyde - metabolism; Methotrexate; Methotrexate - toxicity; Nicorandil - pharmacology; Nicorandil - therapeutic use; Nitric oxide; Nitric Oxide Donors - pharmacology; Nitric Oxide Donors - therapeutic use; Nitric Oxide Synthase Type III - metabolism; Nitric-oxide synthase; Oxidative stress; Oxidative Stress - drug effects; P-Glycoprotein; p53 Protein; Potassium; Pretreatment; Protective Agents - pharmacology; Protective Agents - therapeutic use; Rats, Wistar; Testes; Testis - drug effects; Testis - injuries; Testis - metabolism; Testis - pathology; Testosterone; Testosterone - blood; Toxicity; Tumor necrosis factor-α; Tumor Suppressor Protein p53 - metabolism; Western blotting
• ISSN: 0960-3271; 1477-0903
• DOI: 10.1177/0960327120940361

Methotrexate (MTX) is a widely used chemotherapeutic agent but its clinical use is challenged with different forms of toxicities including testicular injury. The aim of the current study was to evaluate the potential protective effect of potassium channel opener, nicorandil (NIC) (3 and 10 mg/kg/day) on MTX-induced testicular injury in a rat model. Rats were randomly divided into four groups (nine rats each) and treated for 2 weeks as follows: (I) normal control (CON group) received vehicle, (II) model group (MTX group) given MTX (20 mg/kg) single intraperitoneal (i.p.) injection dose on 11th day, (III) MTX + NLD group treated with NIC (3 mg/kg/day) orally for 2 weeks and MTX (20 mg/kg) single i.p. dose on 11th day, and (IV) MTX + NHD group treated with NIC (10 mg/kg/day) orally for 2 weeks and MTX (20 mg/kg) single i.p. injection on the 11th day. The testicular injury was assessed biochemically via serum testosterone, total antioxidant capacity, testicular oxidative stress parameters, P-glycoprotein, tumor necrosis factor-alpha, and interleukin-1β. Furthermore, histopathological evaluation, endothelial nitric oxide synthase (eNOS) immunoexpression, and detection of p53 expression level using Western blotting were performed. Results showed that MTX induced testicular injury which was proved by both biochemical and histopathological evaluations. Our results concluded that NIC pretreatment attenuated MTX-induced testicular injury via significantly increased eNOS immunoexpression, antiapoptotic, anti-inflammatory, and antioxidant properties. Interestingly, NIC high dose is more protective than low dose.